1. Vieweg, J. Immunotherapy for advanced prostate cancer. Rev. Urol. 9 (Suppl. 1), S29–S38 (2007).
2. Schellhammer, P. F. et al. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC) [abstract LBA9]. Presented at the American Urological Association Annual Meeting [ online ], (2009).
3. Vieweg, J. Future directions for vaccine-based therapies. Urol. Oncol. 24, 448–455 (2006).
4. Vieweg, J. & Dannull, J. Technology Insight: vaccine therapy for prostate cancer. Nat. Clin. Pract. Urol. 2, 44–51 (2005).
5. Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909–915 (2005).